BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24412361)

  • 1. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
    Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
    Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B.
    Zhang Y; Yang H; Guo X; Rong N; Song Y; Xu Y; Lan W; Zhang X; Liu M; Xu Y; Cao C
    Protein Cell; 2014 Nov; 5(11):837-50. PubMed ID: 24952722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone demethylase lysine demethylase 5B in development and cancer.
    Han M; Xu W; Cheng P; Jin H; Wang X
    Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
    Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
    FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
    Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
    Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
    Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
    J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
    Li Q; Shi L; Gui B; Yu W; Wang J; Zhang D; Han X; Yao Z; Shang Y
    Cancer Res; 2011 Nov; 71(21):6899-908. PubMed ID: 21937684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).
    Wong PP; Miranda F; Chan KV; Berlato C; Hurst HC; Scibetta AG
    Mol Cell Biol; 2012 May; 32(9):1633-44. PubMed ID: 22371483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
    Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
    J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Peptide Recognition by KDM5B-PHD1: A Case Study.
    Chakravarty S; Essel F; Lin T; Zeigler S
    Biochemistry; 2015 Sep; 54(37):5766-80. PubMed ID: 26266342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
    Bueno MT; Richard S
    Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
    Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
    Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coordinated regulation of retinoic acid signaling pathway by KDM5B and polycomb repressive complex 2.
    Zhang Y; Liang J; Li Q
    J Cell Biochem; 2014 Sep; 115(9):1528-38. PubMed ID: 24619877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
    Xhabija B; Kidder BL
    Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
    Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
    Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
    Enkhbaatar Z; Terashima M; Oktyabri D; Tange S; Ishimura A; Yano S; Suzuki T
    Cell Cycle; 2013 Jul; 12(13):2100-12. PubMed ID: 23759590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone demethylase KDM5B for cancer treatment.
    Fu YD; Huang MJ; Guo JW; You YZ; Liu HM; Huang LH; Yu B
    Eur J Med Chem; 2020 Dec; 208():112760. PubMed ID: 32883639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
    Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
    Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
    Hayami S; Yoshimatsu M; Veerakumarasivam A; Unoki M; Iwai Y; Tsunoda T; Field HI; Kelly JD; Neal DE; Yamaue H; Ponder BA; Nakamura Y; Hamamoto R
    Mol Cancer; 2010 Mar; 9():59. PubMed ID: 20226085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.